<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068495</url>
  </required_header>
  <id_info>
    <org_study_id>119-011</org_study_id>
    <secondary_id>JapicCTI-132390</secondary_id>
    <nct_id>NCT02068495</nct_id>
  </id_info>
  <brief_title>Candesartan Cilexetil/Amlodipine Combination Tablets LD, HD Special Drug Use Surveillance &quot;Hypertension: Long-Term Use&quot;</brief_title>
  <official_title>Unisia Combination Tablets LD, HD Special Drug Use Surveillance &quot;Hypertension: Long-Term Use&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and efficacy of long-term use of candesartan
      cilexetil/amlodipine combination tablets (Unisia Combination Tablets) LD, HD in patients with
      hypertension in the normal clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This special drug use surveillance was designed to investigate the safety and efficacy of
      long-term use of candesartan cilexetil/amlodipine combination tablets (Unisia Combination
      Tablets) in patients with hypertension in the routine clinical setting.

      The usual adult dosage is one tablet (8 mg/2.5 mg or 8 mg/5 mg as candesartan
      cilexetil/amlodipine) administered orally once daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events and adverse drug reactions</measure>
    <time_frame>12 months from the baseline</time_frame>
    <description>Frequency, severity, and time to onset of adverse events and adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure, achievement rate of the target blood pressure levels</measure>
    <time_frame>12 months from baseline</time_frame>
    <description>Calculation of summary statistics for actual measurement values and the change from baseline in systolic and diastolic blood pressure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3409</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Candesartan cilexetil/amlodipine</arm_group_label>
    <description>8 mg/2.5 mg or 8 mg/5 mg, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil/amlodipine</intervention_name>
    <description>Candesartan cilexetil/amlodipine tablets</description>
    <arm_group_label>Candesartan cilexetil/amlodipine</arm_group_label>
    <other_name>Unisia Combination Tablets</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypertension

        Exclusion Criteria:

          -  Patients in whom Unisia is contraindicated [Contraindications]

               1. Patients with a history of hypersensitivity to the ingredients of Unisia or any
                  other dihydropyridine formulations

               2. Women who are pregnant or of child-bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 16, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

